Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC).

Abstract

e15535 Background: Excessive activation of the PI3K/Akt/mTOR pathway is frequently observed in TCC, due to loss of PTEN and/or activating mutation of PIK3CA.We previously showed in a phase II trial...